Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study ; day:7 ; month:8 ; year:2020 ; pages:1-11
Breast cancer research and treatment ; (7.8.2020), 1-11
- Creator
-
Schettini, Francesco
Sobhani, Navid
Ianza, Anna
Triulzi, Tiziana
Molteni, Alfredo
Lazzari, Maria Chiara
Strina, Carla
Milani, Manuela
Corona, Silvia Paola
Sirico, Marianna
Bernocchi, Ottavia
Giudici, Fabiola
Cappelletti, Maria Rosaria
Ciruelos, Eva
Jerusalem, Guy
Loi, Sherine
Fox, Stephen B.
Generali, Daniele
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-020-05856-3
- URN
-
urn:nbn:de:101:1-2020100301132426753884
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Schettini, Francesco
- Sobhani, Navid
- Ianza, Anna
- Triulzi, Tiziana
- Molteni, Alfredo
- Lazzari, Maria Chiara
- Strina, Carla
- Milani, Manuela
- Corona, Silvia Paola
- Sirico, Marianna
- Bernocchi, Ottavia
- Giudici, Fabiola
- Cappelletti, Maria Rosaria
- Ciruelos, Eva
- Jerusalem, Guy
- Loi, Sherine
- Fox, Stephen B.
- Generali, Daniele
- SpringerLink (Online service)
Other Objects (12)
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
Sichere Anwendung von Everolimus
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer
Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
Holz-Surrogate
22: Surrogate
Metall-Surrogate
Opium-Surrogate
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
Sichere Anwendung von Everolimus
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer
Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
Holz-Surrogate
22: Surrogate
Metall-Surrogate
Opium-Surrogate
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
Sichere Anwendung von Everolimus
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer
Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
Holz-Surrogate
22: Surrogate
Metall-Surrogate